Valuation: HighTide Therapeutics, Inc.

Market Cap 1.72B 2B 254M 220M 207M 188M 353M 24.33B 359M 2.42B 946M 12.18B 955M 935M 40.49B P/E 2024
-1.41x
P/E 2025 -5.19x
Enterprise Value 1.34B 1.56B 199M 172M 161M 147M 276M 19B 280M 1.89B 739M 9.52B 746M 730M 31.62B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
63.21%
Yield 2024 *
-
Yield 2025 -
1 day+0.29%
1 week+2.79%
Current month+34.42%
1 month+33.91%
3 months-8.27%
6 months+34.42%
Current year+18.47%
1 week 3.19
Extreme 3.19
3.97
1 month 2.47
Extreme 2.47
3.97
Current year 1.8
Extreme 1.8
4.72
1 year 1.8
Extreme 1.8
4.72
3 years 0.72
Extreme 0.72
13.18
5 years 0.72
Extreme 0.72
13.18
10 years 0.72
Extreme 0.72
13.18
Manager TitleAgeSince
Chief Executive Officer 56 31/12/2010
Director of Finance/CFO 57 30/11/2022
Chief Tech/Sci/R&D Officer - 01/02/2026
Director TitleAgeSince
Chairman 56 -
Director/Board Member 44 14/05/2023
Director/Board Member 68 29/11/2020
Date Insider Type Main position Quantity % Market Cap.
30/04/26 Other

Director

1,800,000 0.3151%
01/04/25 Other

Chief Executive Officer

3,960,550 0.7694%
01/01/25 Other

Chief Executive Officer

2,789,803 0.5420%
Change 5-day change 1-year change 3-year change Capi.($)
+0.29%+2.79%+5.27% - 254M
-1.90%+2.85%+62.82%+104.13% 70.07B
-3.21%-4.32%+31.85%+57.27% 52.87B
-2.05%-5.61%-3.18%+449.71% 27.02B
-1.27%-1.57%+45.90%+8.25% 23.61B
+1.05%-0.62%-18.00%-11.93% 23.38B
+3.81%+20.97%+266.37%+531.28% 19.43B
+0.10%+1.40%+35.36%-19.94% 18.75B
-0.95%-3.52%+19.93%+594.00% 15.85B
+1.24%-5.23%+33.75%+137.66% 12.7B
Average -0.29%+3.73%+48.01%+205.60% 26.39B
Weighted average by Cap. -1.09%+0.57%+50.19%+164.99%

Financials

2024 2025
Net sales - -
Net income -382M -444M -56.61M -48.89M -45.94M -41.78M -78.55M -5.41B -79.85M -538M -210M -2.71B -213M -208M -9.01B -245M -285M -36.32M -31.37M -29.48M -26.81M -50.4M -3.47B -51.23M -345M -135M -1.74B -136M -133M -5.78B
Net Debt -413M -480M -61.2M -52.86M -49.67M -45.18M -84.93M -5.85B -86.33M -582M -228M -2.93B -230M -225M -9.74B -376M -437M -55.74M -48.14M -45.24M -41.14M -77.36M -5.33B -78.63M -530M -207M -2.67B -209M -205M -8.87B
Logo HighTide Therapeutics, Inc.
HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The Company has developed a product pipeline of multiple product candidates in-house, covering many indications in metabolic and digestive diseases among which, some are at clinical-stage. The Company’s core product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases. The Company conducts operations in the United States, Mainland China, Hong Kong and Australia.
Employees
-
Date Price Change Volume
14/08/26 HK$3.495 +0.29% 424,500
13/08/26 HK$3.485 -0.99% 10,566,500
12/08/26 HK$3.520 -4.74% 478,000
11/08/26 HK$3.695 +0.41% 4,356,500
10/08/26 HK$3.680 +8.24% 1,945,000

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 2511 Stock